Data protection Impressum

Pharma

Vaud-based life sciences company Limula has secured CHF 6.2 million to democratize access to life-saving cell and gene therapies.

Limula secures CHF 6.2 million to advance automated cell therapy platform

21 May 2024

Takeda will receive an exclusive option to license AC Immune's ACI-24.060, a breakthrough therapy to combat the progression of Alzheimer's disease, for an upfront payment of USD 100 million and potential milestone payments of USD 2.1 billion.

AC Immune and Takeda sign USD 100 million deal to treat Alzheimer’s disease

13 May 2024

Ikerian AG, along with its subsidiary RetinAI, has successfully completed a USD 6.18 million Series A extension financing round to propel the development and commercial rollout of innovative medical technologies.

Ikerian, parent company of RetinAI, secures USD 6.18 million for AI-driven medical advancements

13 May 2024

EP Equity Investment (EPEI), a company dedicated to investing in promising European companies, has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.

Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment

6 May 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (April 2024)

30 April 2024

Takeda Pharmaceutical has announced a CHF 5 million investment in renewable energy for its Neuchâtel facility.

Takeda commits CHF 5 million to renewable energy for its Neuchâtel site

29 April 2024

Risklick, a spin-off from the University of Bern, has unveiled its cutting-edge software, Protocol AI, designed to transform the landscape of pharmaceutical development.

UniBe spin-off Risklick unveils AI tool to streamline clinical trials

29 April 2024

The latest edition of the Swiss Biotech Report underscores the continued growth and resilience of Switzerland’s biotech sector, attributing success to strong international collaborations and innovative advancements that promise to reshape healthcare worldwide.

The Swiss biotech industry: reliable partners beyond borders

23 April 2024

Isospec Analytics, a Vaud-based start-up specializing in biomolecular analysis, has secured USD 1.9 million in pre-seed funding to advance its revolutionary diagnostic technologies.

Isospec pioneers rapid diagnostic technologies with USD 1.9 million funding

22 April 2024

Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug development.

Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment

9 April 2024

1 2 3 4 5 6 7 8 9 10 … 15